Which has better earnings & valuation, COAG or XENE?

Hemab Therapeutics has higher earnings, but lower revenue than Xenon Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Xenon Pharmaceuticals $7.50M 660.06 -$345.91M -$4.70 N/A

Is COAG or XENE more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Xenon Pharmaceuticals N/A -49.23% -46.42%

Does the media refer more to COAG or XENE?

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than Hemab Therapeutics. MarketBeat recorded 4 mentions for Xenon Pharmaceuticals and 3 mentions for Hemab Therapeutics. Xenon Pharmaceuticals' average media sentiment score of 0.85 beat Hemab Therapeutics' score of 0.00 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, COAG or LEGN?

Hemab Therapeutics has higher earnings, but lower revenue than Legend Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Legend Biotech $1.03B 5.69 -$296.80M -$0.68 N/A

Does the media favor COAG or LEGN?

In the previous week, Legend Biotech had 9 more articles in the media than Hemab Therapeutics. MarketBeat recorded 12 mentions for Legend Biotech and 3 mentions for Hemab Therapeutics. Legend Biotech's average media sentiment score of 0.59 beat Hemab Therapeutics' score of 0.00 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Legend Biotech 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, COAG or DNTH?

Hemab Therapeutics has higher earnings, but lower revenue than Dianthus Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Dianthus Therapeutics $2.04M 2,176.62 -$162.34M -$4.13 N/A

Does the media favor COAG or DNTH?

In the previous week, Dianthus Therapeutics had 4 more articles in the media than Hemab Therapeutics. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 3 mentions for Hemab Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.50 beat Hemab Therapeutics' score of 0.00 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dianthus Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend COAG or NNNN?

Hemab Therapeutics currently has a consensus price target of $41.75, indicating a potential upside of 63.41%. Given Hemab Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Hemab Therapeutics is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hemab Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, COAG or NNNN?

Anbio Biotechnology has higher revenue and earnings than Hemab Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Anbio Biotechnology $8.65M 286.45 $6.40M N/A N/A

Is COAG or NNNN more profitable?

Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Anbio Biotechnology N/A N/A N/A

Which has preferable valuation and earnings, APGE or COAG?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apogee Therapeutics N/A N/A -$255.84M -$4.33 N/A Hemab Therapeutics N/A N/A N/A N/A N/A

Is APGE or COAG more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Apogee Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apogee Therapeutics N/A -32.64% -31.25% Hemab Therapeutics N/A N/A N/A

Does the media prefer APGE or COAG?

In the previous week, Apogee Therapeutics had 4 more articles in the media than Hemab Therapeutics. MarketBeat recorded 7 mentions for Apogee Therapeutics and 3 mentions for Hemab Therapeutics. Apogee Therapeutics' average media sentiment score of 0.62 beat Hemab Therapeutics' score of 0.00 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Hemab Therapeutics (COAG) Competitors

$25.55 +0.25 (+0.99%)

As of 06/8/2026 04:00 PM Eastern

Compare

COAG vs. XENE, LEGN, DNTH, NNNN, and APGE

Should you buy Hemab Therapeutics stock or one of its competitors? MarketBeat compares Hemab Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hemab Therapeutics include Xenon Pharmaceuticals (XENE), Legend Biotech (LEGN), Dianthus Therapeutics (DNTH), Anbio Biotechnology (NNNN), and Apogee Therapeutics (APGE). These companies are all part of the "pharmaceutical products" industry.

How does Hemab Therapeutics compare to Xenon Pharmaceuticals?

Hemab Therapeutics (NASDAQ:COAG) and Xenon Pharmaceuticals (NASDAQ:XENE) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Hemab Therapeutics presently has a consensus target price of $41.75, indicating a potential upside of 63.41%. Xenon Pharmaceuticals has a consensus target price of $77.20, indicating a potential upside of 50.75%. Given Hemab Therapeutics' higher probable upside, research analysts plainly believe Hemab Therapeutics is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Hemab Therapeutics' return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

Hemab Therapeutics has higher earnings, but lower revenue than Xenon Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Xenon Pharmaceuticals	$7.50M	660.06	-$345.91M	-$4.70	N/A

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than Hemab Therapeutics. MarketBeat recorded 4 mentions for Xenon Pharmaceuticals and 3 mentions for Hemab Therapeutics. Xenon Pharmaceuticals' average media sentiment score of 0.85 beat Hemab Therapeutics' score of 0.00 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 4.1% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Xenon Pharmaceuticals beats Hemab Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Hemab Therapeutics compare to Legend Biotech?

Hemab Therapeutics (NASDAQ:COAG) and Legend Biotech (NASDAQ:LEGN) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Hemab Therapeutics has higher earnings, but lower revenue than Legend Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Legend Biotech	$1.03B	5.69	-$296.80M	-$0.68	N/A

Hemab Therapeutics currently has a consensus price target of $41.75, indicating a potential upside of 63.41%. Legend Biotech has a consensus price target of $60.23, indicating a potential upside of 91.09%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Legend Biotech had 9 more articles in the media than Hemab Therapeutics. MarketBeat recorded 12 mentions for Legend Biotech and 3 mentions for Hemab Therapeutics. Legend Biotech's average media sentiment score of 0.59 beat Hemab Therapeutics' score of 0.00 indicating that Legend Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Legend Biotech	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

70.9% of Legend Biotech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Hemab Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Hemab Therapeutics' return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Legend Biotech	-21.98%	-24.92%	-14.87%

Summary

Legend Biotech beats Hemab Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Hemab Therapeutics compare to Dianthus Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Dianthus Therapeutics (NASDAQ:DNTH) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Dianthus Therapeutics had 4 more articles in the media than Hemab Therapeutics. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 3 mentions for Hemab Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.50 beat Hemab Therapeutics' score of 0.00 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dianthus Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hemab Therapeutics has higher earnings, but lower revenue than Dianthus Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Dianthus Therapeutics	$2.04M	2,176.62	-$162.34M	-$4.13	N/A

Hemab Therapeutics presently has a consensus target price of $41.75, indicating a potential upside of 63.41%. Dianthus Therapeutics has a consensus target price of $117.82, indicating a potential upside of 45.06%. Given Hemab Therapeutics' higher probable upside, equities analysts plainly believe Hemab Therapeutics is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Hemab Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. Hemab Therapeutics' return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

Summary

Dianthus Therapeutics beats Hemab Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Hemab Therapeutics compare to Anbio Biotechnology?

Hemab Therapeutics (NASDAQ:COAG) and Anbio Biotechnology (NASDAQ:NNNN) are both manufacturing companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Anbio Biotechnology	N/A	N/A	N/A

Anbio Biotechnology has higher revenue and earnings than Hemab Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Anbio Biotechnology	$8.65M	286.45	$6.40M	N/A	N/A

In the previous week, Hemab Therapeutics had 3 more articles in the media than Anbio Biotechnology. MarketBeat recorded 3 mentions for Hemab Therapeutics and 0 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.11 beat Hemab Therapeutics' score of 0.00 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Hemab Therapeutics	Neutral
Anbio Biotechnology	Positive

Hemab Therapeutics currently has a consensus price target of $41.75, indicating a potential upside of 63.41%. Given Hemab Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Hemab Therapeutics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Hemab Therapeutics beats Anbio Biotechnology on 4 of the 6 factors compared between the two stocks.

How does Hemab Therapeutics compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Hemab Therapeutics (NASDAQ:COAG) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, Apogee Therapeutics had 4 more articles in the media than Hemab Therapeutics. MarketBeat recorded 7 mentions for Apogee Therapeutics and 3 mentions for Hemab Therapeutics. Apogee Therapeutics' average media sentiment score of 0.62 beat Hemab Therapeutics' score of 0.00 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apogee Therapeutics currently has a consensus target price of $114.56, indicating a potential upside of 38.01%. Hemab Therapeutics has a consensus target price of $41.75, indicating a potential upside of 63.41%. Given Hemab Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Hemab Therapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

79.0% of Apogee Therapeutics shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Hemab Therapeutics' return on equity of 0.00% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Hemab Therapeutics	N/A	N/A	N/A

Summary

Apogee Therapeutics beats Hemab Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Hemab Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COAG vs. The Competition

Export

Metric	Hemab Therapeutics	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.19B	$411.83M	$4.24B	$11.99B
Dividend Yield	N/A	N/A	9.68%	5.58%
P/E Ratio	N/A	N/A	21.73	23.74
Price / Sales	N/A	314.52	161.90	107.94
Price / Cash	N/A	N/A	46.51	37.25
Price / Book	N/A	2.55	30.05	6.78
Net Income	N/A	-$81.71M	$118.48M	$337.51M
7 Day Performance	-6.99%	-8.41%	-2.96%	-2.34%
1 Month Performance	1.71%	-12.02%	0.53%	1.88%
1 Year Performance	N/A	N/A	12.12%	25.55%

Hemab Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COAG Hemab Therapeutics	4.3416 of 5 stars	$25.55 +1.0%	$41.75 +63.4%	N/A	$1.19B	N/A	N/A	72	Quiet Period Expiration Gap Up
XENE Xenon Pharmaceuticals	3.8071 of 5 stars	$54.73 -0.1%	$77.20 +41.1%	+61.9%	$5.30B	N/A	N/A	210
LEGN Legend Biotech	4.104 of 5 stars	$27.16 -3.9%	$59.00 +117.2%	-9.9%	$5.02B	$1.14B	N/A	2,965
DNTH Dianthus Therapeutics	3.058 of 5 stars	$93.01 +2.4%	$117.82 +26.7%	+330.9%	$4.97B	$1.34M	N/A	80	Gap Up High Trading Volume
NNNN Anbio Biotechnology	0.8164 of 5 stars	$34.41 -0.1%	N/A	N/A	$4.96B	$8.65M	N/A	27	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COAG) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hemab Therapeutics (COAG) Competitors

COAG vs. XENE, LEGN, DNTH, NNNN, and APGE

How does Hemab Therapeutics compare to Xenon Pharmaceuticals?

Summary

How does Hemab Therapeutics compare to Legend Biotech?

Summary

How does Hemab Therapeutics compare to Dianthus Therapeutics?

Summary

How does Hemab Therapeutics compare to Anbio Biotechnology?

Summary

How does Hemab Therapeutics compare to Apogee Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG vs. The Competition

Hemab Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hemab Therapeutics (COAG) Competitors

COAG vs. XENE, LEGN, DNTH, NNNN, and APGE

How does Hemab Therapeutics compare to Xenon Pharmaceuticals?

Do analysts recommend COAG or XENE?

Is COAG or XENE more profitable?

Which has better earnings & valuation, COAG or XENE?

Does the media refer more to COAG or XENE?

Do institutionals & insiders believe in COAG or XENE?

Summary

How does Hemab Therapeutics compare to Legend Biotech?

Which has higher valuation & earnings, COAG or LEGN?

Do analysts recommend COAG or LEGN?

Does the media favor COAG or LEGN?

Do insiders & institutionals believe in COAG or LEGN?

Is COAG or LEGN more profitable?

Summary

How does Hemab Therapeutics compare to Dianthus Therapeutics?

Do insiders and institutionals believe in COAG or DNTH?

Does the media favor COAG or DNTH?

Which has stronger earnings and valuation, COAG or DNTH?

Do analysts recommend COAG or DNTH?

Is COAG or DNTH more profitable?

Summary

How does Hemab Therapeutics compare to Anbio Biotechnology?

Is COAG or NNNN more profitable?

Which has better valuation and earnings, COAG or NNNN?

Does the media favor COAG or NNNN?

Do analysts recommend COAG or NNNN?

Summary

How does Hemab Therapeutics compare to Apogee Therapeutics?

Which has preferable valuation and earnings, APGE or COAG?

Does the media prefer APGE or COAG?

Do analysts rate APGE or COAG?

Do institutionals and insiders have more ownership in APGE or COAG?

Is APGE or COAG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG vs. The Competition

Hemab Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools